Formex Announces Validation And Launch Of Dedicated Cytotoxic And Potent Handling cGMP Suites At AAPS

SAN DIEGO and SAN ANTONIO, Nov. 11, 2013 /PRNewswire/ -- Formex, LLC ("Formex"), a leader in small molecule formulation and clinical trial manufacturing, announced at the 2013 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting & Exposition in San Antonio, TX the validation and launch of its dedicated suites for R&D and cGMP production capabilities of cytotoxic and potent pharmaceuticals.

(Logo: http://photos.prnewswire.com/prnh/20130718/MM49948LOGO)

"The addition of our cytotoxic and potent handling suites deepens Formex's ability to handle a broader range of active pharmaceutical ingredients (APIs).  Specialized handling of cytotoxic and potent compounds is a strategic complement to our existing technologies for bioavailability enhancement and controlled release technologies," stated Rudy J. Emmelot, President & CEO of Formex.

"Formex is very proud of its 80,000 sq. ft. facility in Torrey Pines, California, and we look forward to continually expanding within our facility to offer more capabilities and dedicated services in formulation and cGMP manufacturing to our clients within the biotech, pharmaceutical, and healthcare industries."

About Formex LLC's Facility

Formex has over 25,000 sq. ft. of cGMP clinical and commercial manufacturing space.  This includes 17 separate and dedicated cGMP suites.  Formex has suites qualified and dedicated for cytotoxic compound handling as well as potent compound handling.

The Formex facility has over 40,000 sq. ft. dedicated to R&D, analytical labs, and cGMP ICH stability storage.

With temperature controlled cGMP warehouses and the entire facility on a dedicated backup generator system, Formex operates a world-class facility of cGMP manufacturing and R&D labs that is among the best for a contract development and manufacturing organization (CDMO).

About Formex LLC

Formex LLC ("Formex"), The Formulation Experts, founded in 2013, is a leading contract development and manufacturing organization focusing on oral and topical dosage forms.  Formex specializes in bioavailability enhancement and controlled release technologies, such as hot melt extrusion, spray drying, fluid bed processing, and liquid/semi-solid filled hard capsules from Pre-Formulation for Solubilization Approach Selection, Formulation Development, Analytical Method Development, Analytical Testing, Pre-Clinical Manufacturing, cGMP Manufacturing for Phase 0-III Clinical Trials & Specialized Commercial Manufacturing.  Formex, LLC is a wholly owned subsidiary of the Biotech Investment Group, LLC.

SOURCE Formex, LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED